AMENDMENTS TO THE CLAIMS

1. (Currently Amended) ~~Composition~~ A composition for the topical treatment of oropharyngeal cavity disorders, ~~characterized in that it comprises~~ comprising an aqueous solution of the salt of diclofenac with tromethamine, ~~in which~~ wherein the amount of ~~the~~ said salt is in an amount of ~~from~~ 0.1% ~~to 0.2%~~ (w/w) and the pH ~~is adjusted between~~ ranges from 7 ~~and~~ to 8.

2. (Canceled)

3. (Currently Amended) ~~Composition~~ The composition according to Claim 1 ~~or 2~~, ~~characterized in that it~~ further ~~comprises~~ comprising a sweetener selected from the group comprising sodium saccharinate, sorbitol, acesulfame and xylitol.

4. (Currently Amended) ~~Composition~~ The composition according to ~~any one of the preceding Claims 1 to 3, characterized in that it further comprises~~ Claim 1, further comprising a preserving agent selected from the group comprising sodium benzoate, methyl p-hydroxybenzoate and propyl p-hydroxybenzoate.

5. (Currently Amended) ~~Composition~~ The composition according to ~~any one of the preceding Claims 1 to 4, characterized in that it further comprises~~ Claim 1, further comprising a gelling agent consisting of a block copolymer of polyethylene glycol and polypropylene glycol.

6. (Currently Amended) ~~Composition~~ The composition according to ~~any one of the preceding Claims 1 to 5, characterized in that it further comprises~~ Claim 1, further comprising a pharmaceutically acceptable flavouring agent.

7. (Currently Amended) ~~Composition~~ The composition according to ~~any one of the preceding Claims 1 to 6, characterized in that it further comprises~~ Claim 1, further comprising a pharmaceutically acceptable colouring agent.

8. (Currently Amended) ~~Composition according to any one of the preceding Claims 1 to 7, characterized in that it is used in the treatment~~ A method of treating a disorder selected from the group consisting of gingivitis, glossitis, stomatitis, aphthae, paradentosis, paradentitis, laryngitis, pharyngitis, mucositis of the oral cavity caused by radiotherapy ~~and~~, mucositis of the oral cavity caused by chemotherapy, ~~and of~~ after-effects of dental surgery ~~and/or~~, and after-effects of general surgery comprising administering to a subject in need thereof an effective amount of the composition according to Claim 1.

9. (New) The method of Claim 8, wherein said administering is orally.

10. (New) The method of Claim 9, wherein said composition is in the form of a mouthwash or an oral spray.

11. (New) A composition for the topical treatment of oropharyngeal cavity disorders, comprising an aqueous solution of the salt of diclofenac with tromethamine, wherein the amount of said salt ranges from 0.1% to 0.2% (w/w) and the pH ranges from 7.6 to 8.

12. (New) The composition according to Claim 11, wherein said salt is in an amount of 0.10% (w/w).

13. (New) The composition according to Claim 11, further comprising a sweetener selected from the group comprising sodium saccharinate, sorbitol, acesulfame and xylitol.

14. (New) The composition according to Claim 11, further comprising a preserving agent selected from the group comprising sodium benzoate, methyl p-hydroxybenzoate and propyl p-hydroxybenzoate.

15. (New) The composition according to Claim 11, further comprising a gelling agent consisting of a block copolymer of polyethylene glycol and polypropylene glycol.

16. (New) The composition according to Claim 11, further comprising a pharmaceutically acceptable flavouring agent.

17. (New) The composition according to Claim 11, further comprising a pharmaceutically acceptable colouring agent.

18. (New) A method of treating a disorder selected from the group consisting of gingivitis, glossitis, stomatitis, aphthae, paradentosis, paradentitis, laryngitis, pharyngitis, mucositis of the oral cavity caused by radiotherapy, mucositis of the oral cavity caused by chemotherapy, after-effects of dental surgery, and after-effects of general surgery comprising

administering to a subject in need thereof an effective amount of the composition according to Claim 11.

19. (New) The method of Claim 18, wherein said administering is orally.

20. (New) The method of Claim 19, wherein said composition is in the form of a mouthwash or an oral spray.

SUPPORT FOR THE AMENDMENTS

Claim 2 has been canceled.

Claims 1 and 3-8 have been amended.

Claims 9-20 have been added.

Claims 1-8 have been amended to improve the overall clarity of these claims and to remove multiple dependencies. Support for the amendment of these claims is provided by the corresponding originally filed claims. The amendment of Claim 1 to limit the amount of the salt is supported by original Claim 2 and page 2, lines 21-27. Claims 8-10 and new Claims 18-20 are supported by the originally filed specification at page 3, lines 16-26. Claims 11-18 correspond to Claims 1-8, but have been limited to a pH range of 7.6 to 8.0. Claims 11-18 are supported by original Claims 1-8 and the specification at pages 1-3 and the Examples (see, for example, Example 1).

No new matter has been added by the present amendments.